Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00558519 · OUTCOME

Disease-free Survival

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia · Source last updated 2026-04-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 8 years post-registration

What was measured

DFS was defined as time from bone marrow response in this study to the earliest occurrence of any of the following: failure to achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) by day 60, death, relapse at any site, or development of second malignant disease.

Groups in this outcome

Treatment (Pediatric Regimen)

Patients received induction (Course I), consolidation (Course II), interim maintenance (Course III), delayed intensification (Course IV), and long-term maintenance therapy (Course V). Please see the "Detailed Description" section for more information.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Pediatric Regimen)295

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Pediatric Regimen)81.7Not reported58.4NAThe 95% confidence interval upper limit was not estimable (below the level of detection).
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The 95% confidence interval upper limit was not estimable (below the level of detection).
        group Id
        OG000
        lower Limit
        58.4
        upper Limit
        NA
        value
        81.7
denoms
  1. counts
    1. group Id
      OG000
      value
      295
    units
    Participants
description
DFS was defined as time from bone marrow response in this study to the earliest occurrence of any of the following: failure to achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) by day 60, death, relapse at any site, or development of second malignant disease.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients received induction (Course I), consolidation (Course II), interim maintenance (Course III), delayed intensification (Course IV), and long-term maintenance therapy (Course V). Please see the "Detailed Description" section for more information.
    id
    OG000
    title
    Treatment (Pediatric Regimen)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 8 years post-registration
title
Disease-free Survival
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice